{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:05:07Z","timestamp":1791821107053,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"same as corresponding author"},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["GlobVac no 234493"],"award-info":[{"award-number":["GlobVac no 234493"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009527","name":"Ministry of Health | Statens Serum Institut","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009527","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Host-directed-therapy strategies are warranted to fight tuberculosis. Here we assess the safety and immunogenicity of adjunctive vaccination with the H56:IC31 candidate and cyclooxygenase-2-inhibitor treatment (etoricoxib) in pulmonary and extra-pulmonary tuberculosis patients in a randomized open-label phase I\/II clinical trial (TBCOX2, NCT02503839). A total of 222 patients were screened, 51 enrolled and randomized; 13 in the etoricoxib-group, 14 in the H56:IC31-group, 12 in the etoricoxib+H56:IC31-group and 12 controls. Three Serious Adverse Events were reported in the etoricoxib-groups; two urticarial rash and one possible disease progression, no Serious Adverse Events were vaccine related. H56:IC31 induces robust expansion of antigen-specific T-cells analyzed by fluorospot and flow cytometry, and higher proportion of seroconversions. Etoricoxib reduced H56:IC31-induced T-cell responses. Here, we show the first clinical data that H56:IC31 vaccination is safe and immunogenic in tuberculosis patients, supporting further studies of H56:IC31 as a host-directed-therapy strategy. Although etoricoxib appears safe, our data do not support therapy with\u00a0adjunctive cyclooxygenase-2-inhibitors.<\/jats:p>","DOI":"10.1038\/s41467-021-27029-6","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T06:02:58Z","timestamp":1637560978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["A Phase I\/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-775X","authenticated-orcid":false,"given":"Synne","family":"Jenum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Tonby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3720-4659","authenticated-orcid":false,"given":"Corina S.","family":"Rueegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"R\u00fchwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1361-3634","authenticated-orcid":false,"given":"Max P.","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6028-0911","authenticated-orcid":false,"given":"Peter","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6889-5873","authenticated-orcid":false,"given":"Inge Christoffer","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7603-419X","authenticated-orcid":false,"given":"Kjersti","family":"Sell\u00e6g","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjerstin","family":"R\u00f8stad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9822-1191","authenticated-orcid":false,"given":"Tehmina","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2841-4697","authenticated-orcid":false,"given":"Kjetil","family":"Task\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Kvale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-3032","authenticated-orcid":false,"given":"Rasmus","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4009-4032","authenticated-orcid":false,"given":"Anne Ma","family":"Dyrhol-Riise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"27029_CR1","unstructured":"WHO. Global tuberculosis report 2019. (Geneva: World Health Organization, Geneva: World Health Organization, 2019)."},{"key":"27029_CR2","first-page":"2149","volume":"373","author":"CR Horsburgh","year":"2015","unstructured":"Horsburgh, C. R., Barry, C. E. & Lange, C. Treat. Tuberculosis 373, 2149\u20132160 (2015).","journal-title":"Treat. Tuberculosis"},{"key":"27029_CR3","doi-asserted-by":"publisher","unstructured":"Tiberi, S. et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/s1473-3099(18)30110-5 (2018).","DOI":"10.1016\/s1473-3099(18)30110-5"},{"key":"27029_CR4","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/S1473-3099(16)00078-5","volume":"16","author":"A Zumla","year":"2016","unstructured":"Zumla, A. et al. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect. Dis. 16, e47\u2013e63 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"27029_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/infdis\/jit152","volume":"208","author":"C Vilaplana","year":"2013","unstructured":"Vilaplana, C. et al. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J. Infect. Dis. 208, 199\u2013202 (2013).","journal-title":"J. Infect. Dis."},{"key":"27029_CR6","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3389\/fimmu.2018.00798","volume":"9","author":"VM Kroesen","year":"2018","unstructured":"Kroesen, V. M. et al. A beneficial effect of low-dose aspirin in a murine model of active tuberculosis. Front. Immunol. 9, 798 (2018).","journal-title":"Front. Immunol."},{"key":"27029_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s42003-019-0530-3","volume":"2","author":"R Mortensen","year":"2019","unstructured":"Mortensen, R. et al. Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice. Commun. Biol. 2, 288 (2019).","journal-title":"Commun. Biol."},{"key":"27029_CR8","first-page":"1536","volume":"7","author":"PJ Cardona","year":"2016","unstructured":"Cardona, P. J. The progress of therapeutic vaccination with regard to tuberculosis. Front. Microbiol. 7, 1536 (2016).","journal-title":"Front. Microbiol."},{"key":"27029_CR9","doi-asserted-by":"publisher","unstructured":"Hatherill, M., White, R. G. & Hawn, T. R. Clinical development of new TB Vaccines: recent advances and next steps. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2019.03154 (2020).","DOI":"10.3389\/fmicb.2019.03154"},{"key":"27029_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nm.2285","volume":"17","author":"C Aagaard","year":"2011","unstructured":"Aagaard, C. et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat. Med. 17, 189\u2013194 (2011).","journal-title":"Nat. Med."},{"key":"27029_CR11","doi-asserted-by":"publisher","first-page":"e55264","DOI":"10.1371\/journal.pone.0055264","volume":"8","author":"A Szabo","year":"2013","unstructured":"Szabo, A. et al. The two-component adjuvant IC31\u00ae boosts type i interferon production of human monocyte-derived dendritic cells via ligation of endosomal TLRs. PLoS ONE 8, e55264 (2013).","journal-title":"PLoS ONE"},{"key":"27029_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1172\/JCI46252","volume":"122","author":"PL Lin","year":"2012","unstructured":"Lin, P. L. et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J. Clin. Investig. 122, 303\u2013314 (2012).","journal-title":"J. Clin. Investig."},{"key":"27029_CR13","doi-asserted-by":"publisher","first-page":"e80579","DOI":"10.1371\/journal.pone.0080579","volume":"8","author":"T Hoang","year":"2013","unstructured":"Hoang, T. et al. ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination. PLoS ONE 8, e80579 (2013).","journal-title":"PLoS ONE"},{"key":"27029_CR14","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1128\/IAI.03030-14","volume":"83","author":"T Hoang","year":"2015","unstructured":"Hoang, T., Agger, E. M., Cassidy, J. P., Christensen, J. P. & Andersen, P. Protein energy malnutrition during vaccination has limited influence on vaccine efficacy but abolishes immunity if administered during Mycobacterium tuberculosis infection. Infect. Immun. 83, 2118\u20132126 (2015).","journal-title":"Infect. Immun."},{"key":"27029_CR15","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3389\/fimmu.2017.01973","volume":"8","author":"R Billeskov","year":"2017","unstructured":"Billeskov, R. et al. High antigen dose is detrimental to post-exposure vaccine protection against tuberculosis. Front. Immunol. 8, 1973 (2017).","journal-title":"Front. Immunol."},{"key":"27029_CR16","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","volume":"33","author":"AK Luabeya","year":"2015","unstructured":"Luabeya, A. K. et al. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine 33, 4130\u20134140 (2015).","journal-title":"Vaccine"},{"key":"27029_CR17","doi-asserted-by":"crossref","unstructured":"Suliman, S. et al. Dose optimization of H56:IC31 vaccine for tuberculosis-endemic populations. a double-blind, placebo-controlled, dose-selection trial. Am. J. Respir. Crit. Care Med. 199, 220\u2013231 (2019).","DOI":"10.1164\/rccm.201802-0366OC"},{"key":"27029_CR18","doi-asserted-by":"publisher","first-page":"100313","DOI":"10.1016\/j.eclinm.2020.100313","volume":"21","author":"LG Bekker","year":"2020","unstructured":"Bekker, L. G. et al. A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa. EClinicalMedicine 21, 100313 (2020).","journal-title":"EClinicalMedicine"},{"key":"27029_CR19","doi-asserted-by":"publisher","unstructured":"Lewinsohn, D. A., Lewinsohn, D. M. & Scriba, T. J. Polyfunctional CD4+ T cells as targets for tuberculosis vaccination. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2017.01262 (2017).","DOI":"10.3389\/fimmu.2017.01262"},{"key":"27029_CR20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri2274","volume":"8","author":"RA Seder","year":"2008","unstructured":"Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8, 247\u2013258 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"27029_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.tube.2016.07.005","volume":"100","author":"P Gillard","year":"2016","unstructured":"Gillard, P. et al. Safety and immunogenicity of the M72\/AS01E candidate tuberculosis vaccine in adults with tuberculosis: a phase II randomised study. Tuberculosis (Edinb., Scotl.) 100, 118\u2013127 (2016).","journal-title":"Tuberculosis (Edinb., Scotl.)"},{"key":"27029_CR22","doi-asserted-by":"publisher","first-page":"e23826","DOI":"10.1371\/journal.pone.0023826","volume":"6","author":"XY Yang","year":"2011","unstructured":"Yang, X. Y., Chen, Q. F., Li, Y. P. & Wu, S. M. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS ONE 6, e23826 (2011).","journal-title":"PLoS ONE"},{"key":"27029_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3892\/br.2016.624","volume":"4","author":"H Weng","year":"2016","unstructured":"Weng, H., Huang, J. Y., Meng, X. Y., Li, S. & Zhang, G. Q. Adjunctive therapy of Mycobacterium vaccae vaccine in the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Biomed. Rep. 4, 595\u2013600 (2016).","journal-title":"Biomed. Rep."},{"key":"27029_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03514-1","volume":"7","author":"SK Sharma","year":"2017","unstructured":"Sharma, S. K. et al. Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial. Sci. Rep. 7, 3354 (2017).","journal-title":"Sci. Rep."},{"key":"27029_CR25","doi-asserted-by":"publisher","first-page":"8047","DOI":"10.4049\/jimmunol.0801592","volume":"182","author":"T Lindenstrom","year":"2009","unstructured":"Lindenstrom, T. et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 182, 8047\u20138055 (2009).","journal-title":"J. Immunol."},{"key":"27029_CR26","doi-asserted-by":"publisher","first-page":"6311","DOI":"10.4049\/jimmunol.1300248","volume":"190","author":"T Lindenstrom","year":"2013","unstructured":"Lindenstrom, T., Knudsen, N. P., Agger, E. M. & Andersen, P. Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells. J. Immunol. 190, 6311\u20136319 (2013).","journal-title":"J. Immunol."},{"key":"27029_CR27","doi-asserted-by":"publisher","first-page":"6557","DOI":"10.1128\/JVI.00073-11","volume":"85","author":"FO Pettersen","year":"2011","unstructured":"Pettersen, F. O. et al. An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J. Virol. 85, 6557\u20136566 (2011).","journal-title":"J. Virol."},{"key":"27029_CR28","doi-asserted-by":"publisher","unstructured":"Sajiki, Y. et al. Prostaglandin E2 induction suppresses the Th1 immune responses in cattle with Johne\u2019s disease. Infect. Immun. https:\/\/doi.org\/10.1128\/iai.00910-17 (2018).","DOI":"10.1128\/iai.00910-17"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27029-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27029-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27029-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T13:14:59Z","timestamp":1669986899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27029-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["27029"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-27029-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"18 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests or other interests that might be perceived to influence the results and\/or discussion reported in this paper. M.R., M.K., P.B., and R.M. are employees at SSI that develop the H56:IC31 vaccine. They are not inventors of patents and have no financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6774"}}